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Introduction: Little is known about genotypic and phenotypic cor-
relations in undifferentiated large-cell carcinoma (LCC) of the lung.
Methods: Thirty LCC were dissected by unsupervised targeted 
next generation sequencing analysis for 50 cancer-associated onco-
genes and tumor suppressor genes. Cell differentiation lineages were 
unveiled by using thyroid transcription factor-1 (TTF1) for adenocar-
cinoma (ADC) and p40 for squamous cell carcinoma (SQC), dichot-
omizing immunohistochemistry (IHC) results for TTF1 as negative 
or positive (whatever its extent) and for p40 as negative, positive, or 
focal (if <10% of reactive tumor cells).
Results: Three LCC were wild type (all TTF1+/p40−), whereas the 
remaining 27 (90%) tumors had at least one gene mutation. Twenty-
four cases featuring TTF1+/p40−, TTF1+/p40±, TTF1−/p40±, or 
TTF1−/p40− phenotypes comprised ATM, BRAF, CDKN2A, EGFR, 
ERBB4, FBXW7, FLT3, KRAS, NRAS, PIK3CA, PTPN11, RET, 
SMAD4, SMO, STK11, or TP53 mutations in keeping with ADC 
lineage, whereas three tumors showing TTF1−/p40+ phenotype 
harbored TP53 only and no ADC-related mutations in keeping with 
SQC lineage. Single, double, triple, quadruple, and quintuple muta-
tions occurred in 16, 6, 2, 2, and 1 patient, respectively. The occur-
rence of three mutations or more but not any immunohistochemistry 
categorization predicted shorter overall survival (OS, p = 0.001) and 
disease-free survival (DFS, p = 0.007), independent of age, sex, and 
tumor stage.
Conclusions: Albeit preliminary also because of the relatively small 
number of LCC under evaluation, this targeted next generation 
sequencing study, however, revealed gene mutation heterogeneity in 
LCC with some genotypic–phenotypic correlations. Negativity or 
focal occurrence of p40 made SQC diagnosis unlikely on molecular 
grounds, but suggested ADC conﬁrming validity of the axiom “no 
p40, no squamous.”
Key Words: Large-cell carcinoma, Lung, Immunohistochemistry, 
Targeted next generation sequencing, p40, TTF1.
(J Thorac Oncol. 2015;10: 1560–1569)
Large-cell carcinoma (LCC) of the lung is a poorly differen-tiated tumor lacking cytological, architectural, and immu-
nohistochemistry (IHC) features of small-cell lung carcinoma 
(SCLC), adenocarcinoma (ADC), or squamous cell carci-
noma (SQC).1 The previous 2004 World Health Organization 
(WHO) classiﬁcation included different histological variants 
under the umbrella term of LCC, namely undifferentiated 
LCC, large-cell neuroendocrine (NE) carcinoma, basaloid 
carcinoma, lymphoepithelioma-like carcinoma, LCC with 
rhabdoid phenotype, and clear cell carcinoma.2 The new 2015 
WHO classiﬁcation has attributed a decisional role to IHC 
characterization of LCC based on a minimalist panel antibody 
approach,3–5 which now are conﬁned to three tumor categories 
only (LCC with null IHC features, LCC with unclear IHC fea-
tures, and LCC with no additional stains).1
In LCC, IHC has been unveiling the same lineage hetero-
geneity,6–13 as previously demonstrated by means of electron 
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microscopy,14,15 indicating that squamous, NE, and especially, 
glandular cell differentiation underlie most LCC, whereas 
completely uncommitted tumors are decidedly uncom-
mon.6,10,11,13,16,17 Among the many IHC biomarkers aimed at 
discovering the hidden face of LCC,6,10,17–19 thyroid transcrip-
tion factor-1 (TTF1)20,21 and Δ(delta)Np63/p40 (henceforth, 
simply p40)22–26 proved the best diagnostic biomarkers to 
highlight ADC and SQC lineages, respectively.3,27–32 Although 
the duet TTF1/p40 remains the most reliable predictor of cell 
lineage and therefore of the ultimate diagnosis in lung can-
cer,3,4,27,33,34 some uncertainty may arise in undifferentiated 
tumors when faced with complete absence of both biomarkers 
(null phenotype: TTF1−/p40−) and focal labeling for squa-
mous differentiation biomarkers, such as p40, in otherwise 
TTF1-negative tumors (unclear phenotype: TTF1−/p40±).
A growing body of information is accumulating about 
the occurrence of nonrandom genetic alterations in deﬁned 
subtypes of lung cancer.4,35–41 New actionable driver genes 
are emerging from the molecular landscape of lung cancer, 
especially when using multiplexed or unbiased technologies 
of next generation sequencing (NGS).42–47 NGS/targeted next 
generation sequencing (T-NGS) data or molecular investiga-
tions on LCC are relatively scant16–18,48,49 for either novelty of 
these technologies or progressive disappearance of such histo-
logical type.11,13 Recent surveys on the subject, however, have 
provided strong evidence that many, if not all, LCC display 
genetic proﬁles (including microRNA expression)18 mostly 
aligned with ADC and/or SQC,16,17,49 but the approach has 
been to correlate a priori-deﬁned IHC diagnoses with under-
lying gene alterations rather than to interpret IHC proﬁles 
according to the relevant mutation portrait.
This study was aimed at establishing the relationship 
between genotype and phenotype in LCC also according to 
tumor categorization of the current 2015 WHO classiﬁca-
tion by comparing their molecular proﬁle assessed by unsu-
pervised T-NGS with stochastically deﬁned IHC categories 
according to biomarkers of glandular and squamous cell 
lineages (TTF1 and p40) and then at a posteriori dissecting 
tumors on the basis of the preferential distribution of gene 
mutations between ADC and SQC.
PATIENTS AND METHODS
Design of the Study
We designed and conducted a two-phase investigation 
to test the relationship between genotype of LCC according 
to T-NGS analysis and phenotype according to TTF1 and p40 
IHC, thereby providing a biological rationale to the diverse 
diagnostic algorithms with particular reference to null and 
unclear phenotypes. In this regard, in the ﬁrst phase, we 
accomplished an unsupervised T-NGS analysis on 30 LCC 
by using a large panel of 50 oncogenes and tumor suppres-
sor genes recurrently altered in human cancers and compared 
molecular results with clinicopathological characteristics of 
patients, including survival. In the second phase, we attributed 
the relevant gene mutations to the diverse IHC-prioritized 
diagnostic algorithms on the basis of their own preferen-
tial distribution in the two major categories of lung cancer, 
i.e., ADC and SQC, to molecularly validate the role of these 
biomarkers in constructing decisional algorithms even in 
undifferentiated tumors.
Patients and Tumors
A series of 30 consecutive surgical specimens of LCC 
from 24 males (range, 47–87 years; mean ± SD, 52.0 ± 14.8 
years) and 6 females (range, 61–72 years; mean ± SD, 
65.5 ± 10.9 years) were identiﬁed in the pathology archives of 
the participant Institutions (Milan, Turin, Modena, and Reggio 
Emilia). The lack of a previous history of cancer elsewhere in 
the body and the availability of complete clinical information 
were required for entering the study. Pertinent data regarding 
the 30 LCC patients as a function of gender, smoking status, 
and tumor stage are summarized in Table 1. Surgical speci-
mens consisted of lobectomy or pneumonectomy along with 
radical mediastinal lymph node resection to ensure accurate 
staging. According to the 7th edition of the tumor, node, 
metastasis (TNM) staging system,50 there were three tumors 
staged IA, nine IB, nine IIA, four IIB, three IIIA, one IIIB, and 
one IV (the latter featuring pT4pN0pM1a). Fifteen patients 
were current smokers and 15 former smokers.
All surgical specimens had been ﬁxed in 4% buffered 
formaldehyde solution for 12 to 24 hours and embedded in 
parafﬁn according to standard histopathological methods. 
All the original hematoxylin and eosin (H&E)-stained sec-
tions were jointly reviewed by some authors (G.P., M.P., 
G.R., and A.C.) without the knowledge of the patients' identi-
ties or original tumor categorization. Solid ADC with mucin 
was excluded by mucin stain,4,41 NE differentiation by mor-
phology and NE biomarkers,2,51-53 sarcomatoid carcinoma by 
morphology and vimentin IHC,54,55 and unexpected metasta-
ses by clinical history and appropriate IHC work-up.3,4,30,31,56 
According to 2004 WHO classiﬁcation on lung cancer pri-
marily based on morphology,2 the study comprised 20 undif-
ferentiated LCC, six LCC–clear cell carcinoma, three LCC 
with rhabdoid phenotype, and one LCC–lymphoepithelioma-
like carcinoma, which were considered poorly differentiated 
by deﬁnition. Out of eight patients with lymph node metasta-
ses, ﬁve were pN1 and three pN2, with involved lymph node 
percentage ranging from 5% to 67%. Vascular invasion was 
seen in 17 tumors and necrosis in 28, the latter ranging from 
10% to 70% of the entire tumor mass. Pleural invasion, clas-
siﬁed according to updated criteria,57 was documented in 15 
tumors, resulting in PL1, PL2, and PL3 in 11, 2, and 2 cases, 
respectively. Tumor size ranged from 10 to 120 mm, with a 
mean value of 41.8 ± 23.8 mm. Complete clinical follow-up 
(updated to July 2014) was available for all but one patient 
lost to follow-up, with OS averaging 47 ± 37 months (median, 
32; range, 1–132). During this period, 13 (44.8%) patients had 
recurrent disease (nine systemic, three in the lungs, and one 
in the brain) and 12 (41.3%) died of disease, with mean DFS 
and OS being 43 ± 38 months (median, 31; range, 1–132) and 
47 ± 37 months (median, 32; range, 1–132), respectively.
Ethics
The study was notiﬁed to and approved by the inde-
pendent ethics committee of the “Fondazione IRCCS Istituto 
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Nazionale Tumori,” Milan, Italy (accession number INT-
145/14). All patients gave their written consent for diagnosis 
and research activities when they were admitted to the hospital.
Sequencing, Fluorescence In Situ Hybridization, 
and Immunohistochemistry Procedures
A detailed description of molecular and IHC laboratory 
procedures we pursued in this investigation, including DNA 
extraction and quantiﬁcation, fluorescence in situ hybridiza-
tion (FISH), T-NGS and Sanger analyses, and the relevant 
antibodies, is reported in Supplemental Digital Content 1 
(http://links.lww.com/JTO/A876) and Table 2, respectively. 
Cutoff of 10% for focal expression of p40 was chosen on the 
basis of recently reﬁned IHC methods.1,3,27,58 The same par-
afﬁn blocks of tumors were used for every type of analysis, 
whether sequencing, FISH, or IHC. In particular, FISH analy-
sis for FGFR1 gene was accomplished in the subsets of tumor 
patients with null (TTF1−/p40−) or unclear (TTF1−/p40±) 
phenotype according to its preferential, albeit not exclusive, 
prevalence in SQC when compared with ADC.59–61
TABLE 1. Characteristics of the 30 Patients with Large-Cell Carcinoma of the Lung
Variable No. Of Patient
Gender Smoking Habit Tumor Stage
Men Women Current Former Stage I Stage II Stages III and IV
30 24 6 15 15 12 13 5
Age
  0–59 7 7 — 3 4 2 4 1
  60–69 12 7 5 8 4 6 2 4
  70+ 11 10 1 4 7 4 7 —
Sex
  Women 6 — 6 5 1 2 1 3
  Men 24 24 — 10 14 10 12 2
Stage
  Stage 1 12 10 2 6 6 12 — —
  Stage 2 13 12 1 6 7 — 13 —
  Stages 3 and 4 5 2 3 3 2 — — 5
LN status
  pN0 22 19 3 12 10 12 9 1
  pN+ 8 5 3 3 5 — 4 4
Smoking status
  Current 15 10 5 15 0 6 6 3
  Former 15 14 1 0 15 6 7 2
Tumor size
  <2 cm 4 4 — 0 4 2 2 —
  2–5 cm 17 14 3 11 6 8 6 3
  >5 cm 9 6 3 4 5 2 5 2
Vascular invasion
  No 13 11 2 5 8 6 6 1
  Yes 17 13 4 10 7 6 7 4
Necrosis (%)
  Absent 2 2 — 0 2 1 1 —
  <20 7 7 — 3 4 4 3 —
  >20 21 15 6 12 9 7 9 5
Pleural invasion
  PL0 15 11 4 4 11 6 5 4
  PL1/2 13 12 1 9 4 6 6 1
  PL3 2 1 1 2 0 — 2 —
Histology
  Clear cell 6 4 2 4 11 2 2 2
  Rhabdoid cell 3 3 — 9 4 2 1 —
  LELC 1 1 — 2 0 1 — —
  Undifferentiated 20 16 4 4 11 7 10 3
LELC, lymphoepithelioma-like carcinoma; LN, lymph node. 
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Statistical Analysis
Qualitative data were compared by Fisher’s exact prob-
ability test or χ2 test as appropriate. OS was deﬁned as the time 
between surgery and the last follow-up or cancer death. If a 
patient died without cancer recurrence, the patient’s survival 
time was censored at the time of death. Only lung cancer-
related deaths or recurrences were considered to be events. 
DFS was calculated from the date of surgery to the date of 
progression or the date of last follow-up. Survival estimates 
were calculated with Kaplan–Meier’s method and compared 
by the log-rank test. The Cox proportional hazard regression 
model was used to evaluate the simultaneous effect of explan-
atory variables on survival time. All analyses were carried-out 
using the SAS statistical software (SAS Institute, Inc., Cary, 
NC). For all tests, only two-sided p values were taken into 
account (with a threshold of <0.05 for statistical signiﬁcance) 
and conﬁdence intervals set at the 95% level.
RESULTS
Mutation Landscape of Large-Cell Carcinoma
Three LCC patients turned out to be wild type, whereas 
the remaining 27 (90%) patients showed 47 recurring muta-
tions in 16 different genes, accounting for 1.7 mutations per 
patient on average. Single, double, triple, quadruple, and quin-
tuple mutations occurred in 16, 6, 2, 2, and 1 patient, respec-
tively (Supplemental Digital Content 2, http://links.lww.com/
JTO/A877 and Table 3). The most frequent alterations affected 
TABLE 2. Antibody Panel Used in the Current Study
Antibodies Clone Source Dilution Pretreatment
Cytokeratin 7 OV-TL 12/30 DAKO, Glostrop, Denmark 1:200 PTLink-EDTA
P40 Polyclonal Calbiochem, Darmstadt, Germany 1:3000 PTLink-EDTA
P40 BC28 Biocare, Concord, CA 1:400 PTLink-EDTA
P53 DO7 DAKO 1:400 PTLink-EDTA
P63 DAKp63 DAKO 1:50 PTLink-EDTA
Thyroid transcription factor-1 8G7/G3/1 DAKO 1:2000 PTLink-EDTA
Synaptophysin DAK-SYNAP DAKO 1:200 PTLink-EDTA
Vimentin V9 DAKO 1:50 PTLink-EDTA
EDTA, ethylenediaminetetraacetic acid; PTLink-EDTA, boiling bath for 30 minutes in EDTA buffer, pH 8.
TABLE 3. Distribution of Gene Mutation and Correlation with p53 Protein Immunohistochemical Expression in the 30 Large-Cell 
Carcinoma Patients Under Evaluation
Samples are displayed in columns and arranged to emphasize mutually exclusive mutations (red boxes). A total of 27 (90%) tumor patients were found to have at least one mutation. 
Blue boxes stand for wild-type samples. In the second row, the distribution of p53 protein expression according to the presence or absence of the relevant mutations is shown.
The patients #19 (exon 6 and 8) and #28 (exon 10) had double mutations for TP53.
Red boxes, mutations; blue boxes, wild-type tumors; yellow boxes, cases with multiple mutations. 
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TP53 gene with 19 mutations in 17 patients, followed by 
KRAS in seven patients; ATM in three patients; BRAF, EGFR, 
FBXW7, NRAS, and PIK3CA in two patients; and CDKN2A, 
ERBB4, FLT3, PTPN11, RET, SMO, SMAD4, and STK11 in 
one patient for every mutation. Eleven patients let multiple 
mutations emerge beyond TP53 (ATM, BRAF, CDKN2A, 
ERBB4, EGFR, FBXW7, KRAS, FLT3, PTPN11, PIK3CA, 
SMAD4, and STK11; Table 3 and Supplemental Digital 
Content 3, http://links.lww.com/JTO/A878). Frequency of 
mutated allelic DNA ranged from 6% (RET) to 76% (ATM), 
with the mean ± SD threshold being 30.0 ± 19.9% for the 16 
mutated genes considered as a whole (Supplemental Digital 
Content 4, http://links.lww.com/JTO/A879). Apart from two 
deletions occurring in TP53 and CDKN2A genes, the other 
mutations comprised 25 transversions and 20 transitions, 
with no signiﬁcant difference among the diverse genes. No 
preferential distribution of mutations was observed according 
to several clinicopathologic variables (age, gender, smoking 
habit, tumor stage or size, histological classiﬁcation, vascular 
or pleural invasion, or necrosis amount). TP53 mutated tumors 
signiﬁcantly overexpressed (p = 0.0019) the relevant protein 
(57.6 ± 42.8%, range 0–100%, median 80%) compared with 
nonmutated tumors (9.0 ± 18.5%, range 0–60%, median 0%; 
Table 3). Moreover, apart from a single patient with TP53 
deletion who did not show any p53 expression, there was a 
trend for stop mutations to downregulate the relevant protein 
(eight cases, 46.2 ± 47.5% tumor cells) compared with non-
stop mutations (10 cases, 76.5 ± 30.8% tumor cells; p = 0.109; 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A878 and Supplemental Digital Content 5, http://links.lww.
com/JTO/A880). To ensure accuracy, BRAF, EGFR, KRAS, 
NRAS, PIK3CA, RET, STK11, and TP53 mutations were rese-
quenced with Sanger method (Supplemental Digital Content 
1, http://links.lww.com/JTO/A876).
Phenotypic Categories of Large-Cell Carcinoma
Five different diagnostic algorithms were obtained by sto-
chastically crossing TTF1 and p40 IHC according to positive, 
negative, and focal categories (Table 4). No signiﬁcant rela-
tionship was found between IHC categories and morphologic 
classiﬁcation of LCC. Relative to IHC, TTF1 decoration var-
ied from 20% to 100% tumor cells (mean ± SD, 61.3 ± 34.5%), 
whereas p40 ranged from 2% to 100% tumor cells (mean ± 
SD, 34.0 ± 39.6%). No signiﬁcant differences were observed 
between p40 polyclonal and monoclonal antibody. Additional 
IHC work-up with p63 and CK7 did not provide useful 
information for better unveiling null or unclear phenotype 
(Supplemental Digital Content 6, http://links.lww.com/JTO/
A881). Representative features of TTF1 and p40 decoration in 
the diverse phenotype combinations are presented in Figure 1, 
where p63 and CK7 stains are also included as picture insets.
Genotypic and Phenotypic Correlations 
of Large-Cell Carcinoma
The distribution of 27 gene-mutated tumor patients 
among the ﬁve categories based on stochastically crossing 
TTF1 and p40 IHC is shown in Table 4, which includes six 
tumors with TTF1+/p40− phenotype, one tumor with TTF1+/
p40± phenotype, three tumors with TTF1−/p40+ phenotype, 
13 tumors with null TTF1−/p40− phenotype, and four tumors 
with unclear TTF1−/p40± phenotype.
Taking advantage of the molecular distribution, all tumors 
negative or only focally positive for p40, regardless of TTF1 
IHC results (categories TTF1+/p40−, TTF1+/p40±, TTF1−/
p40±, and TTF1−/p40−), were molecularly akin to ADC (LCC-
favor ADC), whereas TTF1−/p40+ category was molecularly in 
keeping with SQC for presenting TP53 mutations only along 
with FGFR1 ampliﬁcation in two of three cases (Fig. 2A and B; 
TABLE 4. Morphologic, Immunohistochemistry, and Molecular Correlations in 30 Large-Cell Carcinomas
Category Total
Histologic Classification No. of  
Mutated  
Genes
Wild  
Type
TTF1 %  
(mean ± SD)
P40 %  
(mean ± SD)
IHC  
Phenotype 
Interpretation Gene AlterationsaLCC-U LCC–CCC LCC–LELC LCC-RC
TTF1+/p40− 6 (9b) 5 4 — — 12 3 29.2 ± 38.9 — ADC ATM, ERBB4, FLT3, 
KRAS (2), BRAF, 
NRAS, TP53 (4), 
FBXW7
TTF1+/p40± 1 — — — 1 1 0 98 5 ADC NRAS
TTF1−/p40+c 3 1 1 1 — 3 0 — 83.3 ± 20.8 SQC TP53 (3)
TTF1−/p40− 13 11 1 — 1 25 0 — — ADC ATM (2), BRAF, 
CDKN2A, EGFR 
(2), FBXW&, KRAS 
(4), PIK3CA (2), 
PTPN11, RET, 
STK11, TP53 (9)
TTF1−/p40± 4 3 — — 1 6 0 — 4.2 ± 1.9 ADC KRAS, SMAD4, SMO, 
TP53 (3)
No cases with TTF1+/p40+ phenotype were seen.
aThe number of multiple mutated genes shown in brackets.
bThree patients with TTF1+/p40− phenotype were wild type for the gene mutations being assessed.
cThese tumors also presented with FGFR1 gene ampliﬁcation by fluorescence in situ hybridization analysis in two out of three cases.
LCC-U, large-cell carcinoma-undifferentiated type; LCC–CCC, large-cell carcinoma–clear cell carcinoma type; LCC–LELC, large-cell carcinoma–lymphoepithelioma-like 
carcinoma type; LCC-RC, large-cell carcinoma-rhabdoid cell type; ADC, adenocarcinoma; SQC, squamous cell carcinoma; IHC, immunohistochemistry; SD, standard deviation.
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LCC-favor SQC). FGFR1 FISH analysis was extended to the 
13 tumors with null (TTF1−/p40−) and the four tumors with 
unclear (TTF1−/p40±) phenotypes, ﬁnding that there was only 
1 out of 17 (6%) tumor samples to exhibit FGFR1 gene ampli-
ﬁcation (p = 0.046; Fig. 2C and D).
The 11 tumors harboring multiple mutations corre-
sponded to ADC patients with TTF1+/p40−, TTF1−/p40−, or 
TTF1+/p40± phenotype in 5, 5, and 1 tumor, respectively.
Patient Survival Correlations
General survival of the 30 LCC patients under evaluation 
for both OS and DFS is shown in Supplemental Digital Content 
7 (http://links.lww.com/JTO/A882). Tumor patients expressing 
three mutations or more experienced a shorter OS (p = 0.001) 
and DFS (p = 0.007) independent of tumor stage (p = 0.827) in 
comparison with wild type or up to two gene-mutated patients 
(Fig. 3). Other factors affecting OS and DFS were tumor stage, 
tumor size, and pleural invasion, but none of them or the num-
ber of mutations per patient emerged as independent prognostic 
factors at multivariate analysis. Categorization of LCC accord-
ing to the diverse IHC diagnostic algorithms or morphologic 
subclasses failed to demonstrate any survival implication.
DISCUSSION
In this study, we performed a mutation-based clas-
siﬁcation of LCC by taking advantage of T-NGS for a large 
FIGURE 1. Phenotypic and genotypic correlations of large-cell carcinoma (LCC). Phenotypic and genotypic correlations of 
morphologically defined LCC (A, LCC–CCC; D, LCC-RC; G: LCC–LELC; J,M, LCC-U) between TTF1 (B,E,H,K,N) or p40 (C,F,I,L,O) 
protein expression (along with CK7 and p63 decoration in the insets, respectively), and the relevant gene mutation as derived 
from targeted next generation sequencing analysis. The phenotypes TTF1+/p40− (A,B,C: case #04), TTF1+/p40± (D,E,F: case 
#05), TTF1−/p40− (J,K,L: case #10), and TTF1−/p40± (M,N,O: case #24) underpinned molecular alterations consistent with 
adenocarcinoma, whereas the phenotype TTF1−/p40+ (G,H,I: case #7) showed TP53 mutation only with no other ADC-related 
gene mutations in keeping with the diagnosis of SQC. LCC–CCC, large-cell carcinoma–clear cell carcinoma; LCC-RC, large–
cell carcinoma with rhabdoid cell phenotype; LCC–LELC, large-cell carcinoma–lymphoepithelioma-like carcinoma; and LCC-U, 
large-cell carcinoma-unclassified type; TTF, thyroid transcription factor.
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number of tumor suppressor genes and oncogenes repeatedly 
altered in human cancers. This was compared with a morpho-
logic classiﬁcation and unsupervised IHC diagnostic algo-
rithms of tumors resulting from stochastically crossing two 
highly speciﬁc biomarkers of glandular and squamous cell 
differentiation, namely TTF1 and p40, respectively. At vari-
ance with similar recent works on LCC where tumor diag-
nostic categories were assigned before genotyping according 
to a relatively small number of gene mutations,16–18,48,49 we 
designed this two-phase investigation not only to minimize 
an a priori interpretation of undifferentiated tumors accord-
ing to decisional IHC algorithms suited for conventional 
non–small-cell lung cancer but also to rule out “aberrant/ille-
gitimate” acquisition of biomarkers by undifferentiated tumor 
cells because of loss of relevant cell fate niches or unfaith-
ful expression of nuclear transcription factors. As there were 
some limitations to the study because of the relatively small 
number of LCC under evaluation, the lack of SQC-speciﬁc 
mutations in the 50-gene panel we used for the analysis (such 
as DDR2, KEAP1, and NFE2L2/NRF2), some overlap in the 
mutation scenario between ADC and SQC and the uncertain 
meaning of some uncommon mutations when referring to a 
certain tumor subtype, the results should be better considered 
as preliminary and worthwhile being further conﬁrmed in 
future validation tumor series. The ﬁve possible phenotypic 
categories we encountered in our tumor series (TTF1+/p40+ 
was the only missing phenotype) mirrored to some extent 
the underlying molecular portrait, which was preferentially 
relative to ADC or not excluding SQC when considered as a 
whole thereby allowing a robust biomarker-based classiﬁca-
tion of LCC to be afforded by T-NGS, independent of gender, 
age, and tumor stage. All phenotypic categories were then a 
FIGURE 2. Fluorescence in situ hybridization 
analysis for FGFR1 gene showed gene amplification 
(A) in a p40-positive large-cell carcinoma (B) fulfill-
ing criteria for squamous differentiation lineage (the 
same tumor also presented TP53 mutation but no 
other adenocarcinoma-related gene aberrations). 
By comparison, no FGFR1 amplification (C) was 
observed in a LCC sample exhibiting null (TTF1−/
p40−) phenotype (D, only p40 IHC is shown), which 
fulfilled criteria for adenocarcinoma differentiation 
lineage. LCC, large-cell carcinoma; TTF, thyroid 
transcription factor.
FIGURE 3. Survival analysis accord-
ing to mutation status. Survival curves 
for OS (left side) and DFS (right side) 
according to the number of gene 
mutations per patient, which were not 
affected by age, gender, and tumor 
stage (stage I composed one tumor 
with no mutation, 10 tumors with 1–2 
mutations, and one tumor with ≥3 
mutations versus stages II–IV showing 
2, 12, and 4 tumors in the relevant 
categories, respectively, p = 0.827). 
OS, overall survival; DFS, disease-free 
survival.
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posteriori dissected on the basis of the preferential distribu-
tion of underlying gene mutations between ADC and SQC 
(Table 4 and Supplemental Digital Content 2, http://links.lww.
com/JTO/A877), in the premise that DNA mutations were 
more straightforward and robust than phenotype (potentially 
affected by epigenetic changes). Accordingly, mutations vari-
ably described to cluster in lung ADC, such as ATM, BRAF, 
EGFR, ERBB4, FBXW7, FLT3, KRAS, NRAF, PTPN11, RET, 
STK11, SMAD4, and SMO, albeit not completely speciﬁc for 
this tumor type and possibly with meaning of passenger or 
transitory mutations (destined to be ﬁxed or disappear over 
time), were distributed as a whole into IHC categories uniﬁed 
by absent or only focal (<10%) expression of p40 irrespective 
of TTF1 status thereby supporting the ultimate diagnosis of 
serendipitous ADC or nonsquamous non–small-cell lung can-
cer (a questionable terminology that is, however, largely used 
by oncologists for patient treatment), whereas the complete 
lack of equipollent ADC-related mutations in the three cases 
featuring TTF1−/p40+ phenotype along with the presence of 
TP53 mutation (the most frequently mutated gene in SQC) and 
the co-occurrence of FGFR1 ampliﬁcation in two out of these 
three (66%) cases reinforced the likelihood of really facing 
with undifferentiated SQC.35,36,38,43,49,62 Furthermore, we noted 
that FGFR1 gene ampliﬁcation was uncommon (6%) in non-
squamous-phenotype tumors of our series with null (TTF1−/
p40−) or unclear (TTF1−/p40±) phenotype when compared 
with LCC-squamous (TTF1−/p40+) phenotype (p = 0.046) 
and/or bearing mutations credited to be not so strictly speciﬁc 
for ADC, such as PIK3CA, CDKN2A, FBXW7, FLT3, or 
SMO (Supplemental Digital Content 2, http://links.lww.com/
JTO/A877 and Fig. 2), indicating that these tumors were really 
more akin to ADC than SQC differentiation lineage, in keep-
ing with reported prevalence data of low FGFR1 gene ampliﬁ-
cation in ADC.59–61 In other words, even if certain mutations or 
molecular events are not per se so strictly speciﬁc for a given 
tumor subtype as to be considered transitory or passively pas-
senger tumor determinants, the same mutations or molecular 
events may become meaningful and coherent with that tumor 
type as a whole according to the proper IHC context.17,63–65 
This managerial approach was proven to be particularly useful 
in null (13 cases) or unclear (four cases) phenotypes, which 
were hard to classify because of the simultaneous absence or 
unclear expression of decisional biomarkers and the general 
prudence on the diagnostic interpretation of negative IHC 
algorithms. On the basis of these ﬁndings, we can reasonably 
exclude aberrant/illegitimate expression of either biomarker 
in our series of LCC, conﬁrming molecularly the previously 
proposed IHC axiom “no p40, no squamous,”31,66–68 in keeping 
to which, whenever there is no expression of p40 in the tumor 
cell population, the diagnosis of SQC is extremely unlikely.
Notably, our article indicated that gene mutations were 
frequent (90%) events in LCC, and that approximately 40% of 
patients exhibited multiple mutations (Supplemental Digital 
Content 4, http://links.lww.com/JTO/A879 and Table 3). The 
high mutation rate of LCC correlated with a high frequency 
of mutated allelic DNA and a tobacco exposure-related sig-
nature (our patients were current or former smokers, Table 1) 
in keeping with other lung carcinomas, such as SCLC69,70 or 
ADC.35,36,43 Multiplicity of mutations (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A878 and Supplemental 
Digital Content 4, http://links.lww.com/JTO/A879 and 
Table 3), while offering alternative options of targeted ther-
apy for these life-threatening tumors (13 of our patients had 
recurrent disease and 12 died of disease even if 25 [83%] 
of whom were in stages I and II, Table 1 and Supplemental 
Digital Content 7, http://links.lww.com/JTO/A882), may be 
responsible for secondary resistance development upon target 
therapy by selecting tumor clones and for dismal prognosis 
(Fig. 3) likely because of the involvement of tumor suppressor 
genes and/or accumulating numbers of mutations, as recently 
suggested by multiregion sequencing studies.71
Robustness of our T-NGS results was conﬁrmed by 
means of Sanger resequencing for common mutations or 
IHC correlations for selected protein expression such as 
p53 (Supplemental Digital Content 5, http://links.lww.com/
JTO/A880). The number of genes in our tumor series was 
greater than previously assessed in other similar works,16,17,48,49 
revealing 16 different gene mutations underlying diverse 
biological mechanisms (Supplemental Digital Content 2, 
http://links.lww.com/JTO/A877). Most of these mutations 
preferentially split into ADC or SQC, but some of the less 
frequently described mutations in lung cancer and in pulmo-
nary ADC, such as ERBB4, FBXW7, FLT3, NRAS, PTPN11, 
RET, SMAD4 and SMO, were interpreted as belonging to the 
ADC category not only on the basis of available gene muta-
tion catalogues and the absence of FGFR1 ampliﬁcation in 
these tumors, but also of the relevant IHC proﬁles all basically 
dominated by p40 negativity or focal (<10%) occurrence irre-
spective of TTF1 status.
It could be speculated that LCC null/unclear phenotypes 
represent variant of TTF1-negative ADC, which may account 
up to 20% of morphological ADC,20 whereas absence or focal 
presence of p40 is unlikely to occur in SQC,27,31 inasmuch as 
p40 acts as a master regulator of epidermal cell fate trans-acti-
vating genes of basal keratins.66–68 In keeping with our ﬁndings, 
other studies dealing with speciﬁc microRNA prevalence18 or 
different mutation proﬁles16,17 supported the notion that TTF1/
p40 double-negative LCC would be more akin to ADC, once 
NE tumors, sarcoma, melanoma, or unexpected metastasis was 
ruled out. Focal p40 decoration in otherwise TTF1-negative 
LCC showing mutation traits of ADC could even underline 
focal squamous/basal-like (co)-lineage within individual tumor 
cells of ADC31,63,72–74 rather than an aberrant/illegitimate expres-
sion of these non-TA isoforms in ADC-differentiated LCC.
Tumor categories unveiled by IHC did not change if 
different antibodies to p40 were used, whether polyclonal or 
monoclonal, this indicating that both reagents pinpointed the 
same tumor cells in keeping with previously reported ﬁnd-
ings.31 Gene associations beyond TP53 were seen for KRAS 
with ATM, FLT3, PTPN11, PIK3CA, STK11, and SMAD4 
and for EGFR with FBXW7 (Table 3 and Supplemental 
Digital Content 3, http://links.lww.com/JTO/A878), suggest-
ing different activation pathways in the development of LCC 
(Supplemental Digital Content 4, http://links.lww.com/JTO/
A879), but further investigation on a larger number of LCC is 
clearly warranted to conﬁrm these preliminary data.
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CONCLUSIONS
This is a preliminary molecular study based on T-NGS, 
which suggests—in keeping with IHC ﬁndings—that most 
LCC basically pinpoint ADC with a minority of SQC, and that 
p40-based and TTF1-based IHC proﬁling is likely to mirror 
underlying differentiation lineages. This conclusion paves the 
way to an innovative and clinically oriented classiﬁcation of 
LCC19 resulting from integration of gene mutation and IHC 
proﬁles to successfully align with precision medicine require-
ments (the right drug, to the right patient, at the right time).
In summary, the main ﬁndings of our paper are:
1. LCC basically underlie dual cell lineages based on T-NGS 
and p40/TTF1 proﬁling;
2. ΔNp63/p40 positivity unveils SQC while negativity under-
pins ADC in keeping with T-NGS to sustain the axiom “no 
p40, no squamous”;
3. Null or unclear phenotype corresponds to ADC by merging 
molecular and IHC grounds;
4. Integrating T-NGS and IHC may result in a clinically 
oriented classiﬁcation on LCC.
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